HDAC1/2 maintain TERT mRNA stability in TERT-rearranged neuroblastoma
Genomic TERT locus rearrangements define an aggressive high-risk neuroblastoma subgroup characterized by enhancer hijacking, high-level TERT expression and continuous telomerase activation. Although these structural alterations supply a strong transcriptional drive, the post-transcriptional mechanisms preserving TERT mRNA presence remain incompletely understood. We identified histone deacetylases 1 and 2 (HDAC1/2) as essential post-transcriptional guardians of TERT mRNA stability in TERT-rearranged neuroblastoma. Pharmacological inhibition or RNAi-mediated depletion of HDAC1 and HDAC2, but not HDACs 3-11, rapidly downregulated TERT transcript levels and suppressed telomerase enzymatic activity. Transcript decay kinetics following transcriptional arrest with actinomycin D confirmed that HDAC1/2 blockade accelerates TERT mRNA decay, reducing transcript half-life by 30-47%. High-resolution ChIP-seq profiling across the translocation breakpoint demonstrated HDAC inhibition does not alter local chromatin accessibility. Array-based DNA methylation profiling showed only a mild, non-specific global reduction in CpG island methylation upon panobinostat exposure and no focal correlation with TERT transcript loss across the breakpoint locus. Depleting TERT mRNA via HDAC1/2 inhibition dismantled a core 50-gene TERT-associated oncogenic expression network. Ectopic re-expression of TERT cDNA partially rescued cellular viability and normalized expression of key signature genes despite continuous HDAC inhibition. HDAC1/2 inhibition significantly attenuated tumor growth, reduced intratumor TERT expression and prolonging overall survival in both preventive and therapeutic TERT-rearranged xenograft mouse models. Our data establish a post-transcriptional rather than transcriptional mode of TERT regulation and confirm tumor suppression is partly driven by depleting TERT transcripts, uncovering a HDAC1/2 dependency in TERT-driven neuroblastoma. We provide a molecular rationale for therapeutic strategies disrupting HDAC1/2-mediated TERT mRNA stabilization.
Authors
- Anton George Henssen (ORCID: https://orcid.org/0000-0003-1534-778X)
- Annika Spruessel
- Annabell Szymansky (ORCID: https://orcid.org/0000-0003-4797-4526)
- Charlotte Gatzweiler
- Rocío Chamorro González (ORCID: https://orcid.org/0000-0002-5653-7259)
- Kathrin Hauptmann (ORCID: https://orcid.org/0000-0003-0590-3674)
- Konstantin Helmsauer (ORCID: https://orcid.org/0000-0003-0773-4114)
- January Mikolaj Weiner (ORCID: https://orcid.org/0000-0003-1438-7819)
- Steffen Fuchs (ORCID: https://orcid.org/0000-0001-9619-4329)
- Sabine Finkler (ORCID: https://orcid.org/0000-0001-8648-914X)
- Hedwig E. Deubzer (ORCID: https://orcid.org/0000-0002-6115-4893)
- Marco Lodrini (ORCID: https://orcid.org/0000-0003-4434-529X)
- Angelika Eggert (ORCID: https://orcid.org/0000-0003-3476-8184)
- Dieter Beule (ORCID: https://orcid.org/0000-0002-3284-0632)
- Jan F. Hollander (ORCID: https://orcid.org/0009-0001-2907-2206)
- Sveva Castelli (ORCID: https://orcid.org/0000-0001-7660-5354)
- Anja A. Kuehl
- Franziska Schulze (ORCID: https://orcid.org/0009-0008-6237-5111)
- Nils Bluethgen
Institutions
- Institute for Research in Biomedicine (ES)
- Barcelona Institute of Science and Technology (ES)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-17
- DOI
- https://doi.org/10.64898/2026.11.15.766789
- Primary Topic
- Neuroblastoma Research and Treatments
- Type
- preprint
Funders
- Deutsches Krebsforschungszentrum
- European Commission
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung